Novo Nordisk (NOVO) EGM 2025 summary

Opening remarks and agenda

• Meeting convened virtually, with translation and interactive shareholder Q&A.

• Foundation and Novo Holdings proposals followed governance disagreements; Mikael Dolsten withdrew his candidacy.

Specific resolutions to be voted on

• Lars Rebien Sørensen elected Chair, Cees de Jong Vice Chair, and Britt Meelby Jensen and Stephan Engels Board members; terms run through the AGM on 26 March 2026.

• Helge Lund, Henrik Poulsen, Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay stepped down; employee representatives remain until 2026.

Board and executive committee updates

• Outgoing Board cited market value doubling since 2020, net sales rising 129%, operating profit 137% and R&D investment 211%.

• Mike Doustar was appointed CEO in July, with full Foundation support.